Altimmune's MASH Drug Shows Durable Liver, Weight Loss Gains At 48 Weeks

Altimmune Inc. (NASDAQ:ALT) on Friday shared topline results from the IMPACT Phase 2b trial of pemvidutide. Patients had metabolic dysfunction-associated steatohepatitis (MASH) at 48 weeks.MASH is a liver disease marked by excess liver fat (steatosis) alongside inflammation and liver cell damage.Topline 48-week data from the IMPACT trial showed that treatment with pemvidutide achieved statistically significant improvements across treatment arms in key noninvasive tests, including Enhanced Liver Fibrosis and ...